Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
Authors:
Open Access
- 15 January 2012
- journal article
- research article
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2012, 1-7
Abstract
Background. We performed a randomized phase II study comparing efficacy and toxicity of weekly paclitaxel 80 mg/m2(Weetax) with three weekly docetaxel 75 mg/m2(Threetax), both in combination with oral capecitabine 1000 mg/m2twice daily for 2 weeks followed by a 1-week break.Patients. Thirty-seven women with confirmed metastatic breast cancer were randomized.Results. Median TTF was 174 (Weetax) versus 147 days (Threetax) (). Median OS was 933 (Weetax) versus 464 days (Threetax) (). Reasons for TTF were PD 8/18 (Weetax), 9/19 (Threetax); and toxicity: 8/18 (Weetax), 8/19 (Threetax). ORR was 72% (Weetax) versus 26% (Threetax) (). The Threetax-combination resulted in a higher incidence of leuco-/neutropenia compared to Weetax. Grade II anemia was more pronounced in the Weetax group. No difference was found in quality of life.Conclusion. Taxanes in combination with capecitabine resulted in a high level of toxicity. Taxanes and capecitabine should be considered given sequentially and not in combination.Keywords
This publication has 17 references indexed in Scilit:
- Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsJournal of Clinical Oncology, 2011
- Dose-finding study of capecitabine in combination with weekly paclitaxel for patients with anthracycline-pretreated metastatic breast cancer.2007
- Phase II Trial of Capecitabine and Weekly Paclitaxel As First-Line Therapy for Metastatic Breast CancerJournal of Clinical Oncology, 2006
- Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOLAnnals of Oncology, 2005
- Capecitabine with Weekly Paclitaxel for Advanced Breast Cancer: A Phase I Dose-Finding TrialOncology, 2004
- Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancerActa Oncologica, 2004
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancerClinical Oncology, 1996
- A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclinesEuropean Journal of Cancer, 1996